Press releases
- Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
- Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
- Innate Pharma Announces Its Participation in Upcoming Investor Conferences
- Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting
- Outcome of Innate Pharma’s 2024 Annual General Meeting
- Innate Pharma: Clarification Regarding SAR443579 Designation
- Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress
- Innate Pharma Reports First Quarter 2024 Business Update and Financial Results
- Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update
- Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024
More ▼
Key statistics
On Monday, Innate Pharma SA (IDD:DUS) closed at 2.11, 5.61% above its 52-week low of 2.00, set on Oct 05, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.11 |
---|---|
High | 2.11 |
Low | 2.11 |
Bid | -- |
Offer | -- |
Previous close | 2.11 |
Average volume | 89.38 |
---|---|
Shares outstanding | 80.86m |
Free float | 60.59m |
P/E (TTM) | -- |
Market cap | 171.83m EUR |
EPS (TTM) | -0.0939 EUR |
Data delayed at least 15 minutes, as of Jun 17 2024 07:11 BST.
More ▼